BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35699562)

  • 1. The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in Psoriasis.
    Fang H; Hou Y; Zhuang H; Wang C
    New Microbiol; 2022 Apr; 45(2):130-137. PubMed ID: 35699562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
    Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
    Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of moxibustion on skin lesions and immune inflammatory response in psoriasis mice].
    Meng YJ; Liu Y; Liu ZR; Chen ZX; Di TT; Zhao JX; Wang Y; Li P
    Zhongguo Zhen Jiu; 2022 Jan; 42(1):66-72. PubMed ID: 35025160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis.
    Kubin ME; Kokkonen N; Palatsi R; Hägg PM; Väyrynen JP; Glumoff V; Haapasaari KM; Hurskainen T; Tasanen K
    Acta Derm Venereol; 2017 Apr; 97(4):449-455. PubMed ID: 27868150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of fire needling on imiquimod induced psoriasis-like lesion and STAT3 pathway in mice].
    Feng F; Wang Y; Zhao JX; Di TT; Meng YJ; Chen ZX; Qi C; Hu XQ; Wang YZ; Li P
    Zhongguo Zhen Jiu; 2022 May; 42(5):541-8. PubMed ID: 35543945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
    Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
    J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity.
    Wu LT; Qiao ZH; Tian JB; Lin JL; Hou SC; Liu XM
    Skin Res Technol; 2023 Jul; 29(7):e13405. PubMed ID: 37522491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis.
    Wang X; Kaiser H; Kvist-Hansen A; McCauley BD; Skov L; Hansen PR; Becker C
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decryption of Active Constituents and Action Mechanism of the Traditional Uighur Prescription (BXXTR) Alleviating IMQ-Induced Psoriasis-Like Skin Inflammation in BALB/c Mice.
    Pang X; Zhang K; Huang J; Wang H; Gao L; Wang T; Sun Y; Chen L; Wang J
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
    Furue K; Ito T; Furue M
    Cytokine; 2018 Nov; 111():182-188. PubMed ID: 30172115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Khasianine ameliorates psoriasis-like skin inflammation and represses TNF-α/NF-κB axis mediated transactivation of IL-17A and IL-33 in keratinocytes.
    Yang Y; Zhang Y; Chen X; Su Z; Deng Y; Zhao Q
    J Ethnopharmacol; 2022 Jun; 292():115124. PubMed ID: 35183690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potency of common proinflammatory cytokines measurement for revealing the risk and severity of anxiety and depression in psoriasis patients.
    Tong N; Zhang Y; Yang A; Dai X; Hao S
    J Clin Lab Anal; 2022 Sep; 36(9):e24643. PubMed ID: 35944185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
    Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
    Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the mechanism of Fang-Ji-Di-Huang-Decoction in ameliorating psoriasis-like skin inflammation via the inhibition of IL-23/Th17 cell axis.
    Song C; Yang C; Meng S; Li M; Wang X; Zhu Y; Kong L; Lv W; Qiao H; Sun Y
    J Ethnopharmacol; 2021 Dec; 281():114571. PubMed ID: 34464701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.
    Bovenschen HJ; van de Kerkhof PC; van Erp PE; Woestenenk R; Joosten I; Koenen HJ
    J Invest Dermatol; 2011 Sep; 131(9):1853-60. PubMed ID: 21654831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages.
    Brunner PM; Koszik F; Reininger B; Kalb ML; Bauer W; Stingl G
    J Allergy Clin Immunol; 2013 Nov; 132(5):1184-1193.e8. PubMed ID: 23890755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-36γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease.
    Friedrich M; Tillack C; Wollenberg A; Schauber J; Brand S
    Inflamm Bowel Dis; 2014 Nov; 20(11):1891-901. PubMed ID: 25299544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis.
    Yu Q; Tong Y; Cui L; Zhang L; Gong Y; Diao H; Gao F; Shi Y
    Int Immunopharmacol; 2019 Aug; 73():442-450. PubMed ID: 31154289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the efficacy and safety of plaque psoriasis treatment by TNF-α and IL-17A inhibitor biologics in patients who received the inactivated SARS-CoV-2 vaccine.
    Ye S; Sun H; Xu Z; Xu B; Wu N; Wu J
    Immun Inflamm Dis; 2023 Jul; 11(7):e938. PubMed ID: 37506146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.